{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Defined as the percentage of patients in whom an achieved R0 resection was achieved during surgery.","groups":[{"description":"Patients receive 8 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.","id":"OG000","title":"Arm 1 (mFOLFIRINOX + Surgery + FOLFOX)"},{"description":"Patients receive 7 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients receive radiation therapy then undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.","id":"OG001","title":"Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx)"}],"paramType":"NUMBER","populationDescription":"Excluded from analysis were 6 patients that withdrew or progressed prior to treatment.","reportingStatus":"POSTED","timeFrame":"24 months","title":"Residual Tumor (R)0 Resection Rate","type":"SECONDARY","unitOfMeasure":"percentage of patients"}